KaloBios Pharmaceuticals to price initial public sale of common stock

Bookrunner Leerink Swann helps fund clinical trials, working capital

By Devika Patel

Knoxville, Tenn., Oct. 5 - KaloBios Pharmaceuticals, Inc. will price its initial public offering of common stock, according to a Form S-1 filed Friday with the Securities and Exchange Commission. It expects its shares to trade on the Nasdaq exchange under the symbol "KBIO."

The deal also has a 30-day over-allotment option. The company registered $60 million of shares, which includes those sold as part of the greenshoe.

Leerink Swann is the sole bookrunning manager. William Blair is the lead manager, and Needham & Co. is the co-manager.

Proceeds will be used to develop and advance product candidates through clinical trials as well as for working capital and general corporate purposes.

The biopharmaceutical company is based in San Francisco.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.